This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Hatch-Waxman and Product Exclusivity Issues in the IP Due Diligence Context

January 2008, Pharma/Biotech IP Due Diligence Conference, New York, NY

Share this article: